Sorafenib Completed Phase 1 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00384969Sorafenib and RAD001 Renal Cell Carcinoma